Association of insulin resistance and non-alcoholic fatty liver disease

BACKGROUND: The number of patients with chronic metabolic disorders such as obesity, type 2 diabetes mellitus (T2D) and non-alcoholic fatty liver disease (NAFLD) is growing at an alarming rate worldwide in both developed and developing countries. In the world, the prevalence of NAFLD is approaching 25%. Among patients with T2D, 70–80% are diagnosed with NAFLD. Insulin resistance (IR) is recognized as one of the main pathogenetic factors in the development of the most common chronic liver disease — NAFLD.

AIM: Our search work was aimed at determining the contribution of the degree of IR to the progression of NAFLD; compare the gold standard for the determination of IR (clamp) and the mathematical model (HOMA-IR).

METHODS: An observational one-stage open comparative study was conducted on the basis of the case-control principle. The objects of the study were overweight and obese patients who had not previously been diagnosed carbohydrate metabolism disorders, without secondary causes of fat accumulation in the liver. During the examination, clinical and laboratory studies were carried out, IR indices (M-index, HOMA-IR index) were obtained, a diagnosis of carbohydrate metabolism disturbance (or its absence) was made, a liver biopsy was made, morphological and clinical diagnoses were made.

RESULTS: The analysis included information about 60 patients, they are divided into 3 groups: without NAFLD (7 people), with steatosis (18 people), with non-alcoholic steatohepatitis (NASH) (35 people), groups are comparable by age, gender, and body mass index (BMI), glycated hemoglobin. When assessing the degree of IR using the hyperinsulinemic euglycemic clamp test, 19 showed a severe degree of IR, 28 had a moderate degree, 8 had a mild degree, and 5 had no IR. In the three studied groups, the median IR corresponded to an average degree and did not significantly differ. When comparing the gold standard for determining IR and the mathematical model (HOMA-IR) in the studied groups, an negative significant correlation was revealed (p = 0,0001).

CONCLUSIONS: In the course of our study, no correlation was found between the degree of IR and the severity of NAFLD. This result allows us to think about other pathogenetic factors that affect the progression of NAFLD.

1. Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004

2. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922. https://doi.org/10.1038/s41591-018-0104-9

3. International Diabetes Federation. IDF Diabetes Atlas. 2019. Available from: https://www.diabetesatlas.org/data/en/country/94/id.html

4. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.). https://doi.org/10.14341/DM221S1

5. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2(7525):1051-1056.

6. Sanyal AJ, Campbell–Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120(5):1183-1192. https://doi.org/10.1053/gast.2001.23256

7. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome. Diabetes. 2001;50(8):1844-1850. https://doi.org/10.2337/diabetes.50.8.1844

8. George J, Liddle C, Samarasinghe D, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373-379 https://doi.org/10.1053/jhep.2002.30692.

9. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450-455. https://doi.org/10.1016/S0002-9343(99)00271-5

10. Cцmert B, Mas MR, Erdem H, et al. Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis. 2001;33(4):353-358.

11. Barrows BR, Parks EJ. Contributions of Different Fatty Acid Sources to Very Low-Density Lipoprotein-Triacylglycerol in the Fasted and Fed States. J Clin Endocrinol Metab. 2006;91(4):1446-1452. https://doi.org/10.1210/jc.2005-1709

12. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351. https://doi.org/10.1172/JCI23621

13. Tsvetkova MV, Khirmanov VN, Zybina NN. The role of nonesterified fatty acids in pathogenesis of cardiovascular diseases. Arterial Hypertension. 2010;16(1):93-103. (In Russ.). https://doi.org/10.18705/1607-419X-2010-16-1-93-103

14. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1389-1397. https://doi.org/10.1002/hep.25539

15. Armstrong MJ, Hazlehurst JM, Hull D, et al. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis. Diabetes Obes Metab. 2014;16(7):651-660. https://doi.org/10.1111/dom.12272

16. Kempinska-Podhorodecka A, Wunsch E, Milkiewicz P, et al. The Association between SOCS1−1656G>A Polymorphism, Insulin Resistance and Obesity in Nonalcoholic Fatty Liver Disease (NAFLD) Patients. J Clin Med. 2019;8(11):1912. https://doi.org/10.3390/jcm8111912

17. Loomba R, Schork N, Chen C-H, et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015;149(7):1784-1793. https://doi.org/10.1053/j.gastro.2015.08.011

18. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367

19. IDF W. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia Report of a WHO/IDF consultation. 2006. 50 р.

20. Mayorov AYu. Sostoyanie insulinoresistentnosti v evolyucii saharnogo diabeta 2 tipa. [dissertation]. Moscow; 2009. (In Russ.).

21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and в-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. https://doi.org/10.1007/BF00280883

22. Gayoso-Diz P, Otero-Gonzбlez A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13(1):47. https://doi.org/10.1186/1472-6823-13-47

23. Ivashkin VT, Mayevskaya MV,Pavlov ChS, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientifi Liver Society and the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):4-42 (In Russ.). https://doi.org/10.22416/1382-4376-2016-26-2-24-42

24. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634-642. https://doi.org/10.1007/s00125-005-1682-x

25. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship Between Hepatic/ Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. Gastroenterology. 2007;133(2):496-506. https://doi.org/10.1053/j.gastro.2007.04.068

26. Goodpaster BH, Leland Thaete F, Simoneau J-A, Kelley DE. Subcutaneous Abdominal Fat and Thigh Muscle Composition Predict Insulin Sensitivity Independently of Visceral Fat. Diabetes. 1997;46(10):1579-1585. https://doi.org/10.2337/diacare.46.10.1579

27. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports. 2019;1(4):312-328. https://doi.org/10.1016/j.jhepr.2019.07.002

28. Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects. J Clin Endocrinol Metab. 2011;96(6):1763-1770. https://doi.org/10.1210/jc.2010-2146

29. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64(2):399-408. https://doi.org/10.1016/j.jhep.2015.08.038

30. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebocontrolled phase 2 study. Lancet. 2016;387(10019):679-690. https://doi.org/10.1016/S0140-6736(15)00803-X

31. Macauley M, Hollingsworth KG, Smith FE, et al. Effect of Vildagliptin on Hepatic Steatosis. J Clin Endocrinol Metab. 2015;100(4):1578-1585. https://doi.org/10.1210/jc.2014-3794

32. Joy TR, McKenzie CA, Tirona RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebocontrolled trial. World J Gastroenterol. 2017;23(1):141. https://doi.org/10.3748/wjg.v23.i1.141

33. Alam S, Ghosh J, Mustafa G, et al. Effect of sitagliptin on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Hepat Med. 2018;(10):23-31. https://doi.org/10.2147/HMER.S158053

34. Kuchay MS, Krishan S, Mishra SK, et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801-1808. https://doi.org/10.2337/dc18-0165

35. Bajaj HS, Brown RE, Bhullar L, et al. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. Diabetes Metab. 2018;44(6):493-499. https://doi.org/10.1016/j.diabet.2018.08.001

36. Seko Y, Sumida Y, Sasaki K, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53(1):140-151. https://doi.org/10.1007/s00535-017-1364-8

37. Seko Y, Nishikawa T, Umemura A, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Diabetes Metab Syndr Obes. 2018;11:835-843. https://doi.org/10.2147/DMSO.S184767.

38. Lai L-L, Vethakkan SR, Nik Mustapha NR, , et al. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci. 2020;65(2):623-631. https://doi.org/10.1007/s10620-019-5477-1

39. Belfort R, Harrison SA, Brown K, et al. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. N Engl J Med. 2006;355(22):2297-2307. https://doi.org/10.1056/NEJMoa060326

40. Aithal GP, Thomas JA, Kaye P V., et al. Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis. Gastroenterology. 2008;135(4):1176-1184. https://doi.org/10.1053/j.gastro.2008.06.047

41. Sanyal AJ, Chalasani N, Kowdley K V, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. https://doi.org/10.1056/NEJMoa0907929

42. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Ann Intern Med. 2016;165(5):305. https://doi.org/10.7326/M15-1774

43. Bril F, Kalavalapalli S, Clark VC, et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558-566.e2. https://doi.org/10.1016/j.cgh.2017.12.001

44. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. JAMA Intern Med. 2017;177(5):633. https://doi.org/10.1001/jamainternmed.2016.9607

45. Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178-2187. https://doi.org/10.1002/hep.26988

46. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005;41(2):372-379. https://doi.org/10.1002/hep.20554

47. Sreekumar R. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 2003;38(1):244-251 ttps://doi.org/10.1053/jhep.2003.50290